It appeared, as a peptide native and stable in human gastric juice, as a late outbreak of the cytoprotection/organoprotection concept of Robert and Szabo, a concept mostly from the stomach studies [10,11,12,13,14,15,16,17] for epithelial and endothelial protection, like the previous theoretical/practical breakthroughs in the 1980s and braingut axis and gutbrain axis (for review, see, i.e., [2,3,4,5,6,7,8])
13 When comparing the active GLP-2R structure with the GLP-1-bound GLP-1R structure, 13 the extracellular end of TM1 in GLP-2R is extended by six additional residues, thereby bending toward GLP-2 with the formation of additional hydrogen bond and hydrophobic contacts
The clinician chooses semaglutide, drawing insights from landmark trials (including data from the LEAD study on liraglutide and parallel findings with semaglutide) (16)
Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials